A Modern Design for a Phase 2/3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BHV-7000 in Idiopathic Generalized Epilepsy with Generalized Tonic-Clonic Seizures (P8-9.016)
Describe the rationale and design of a registrational clinical trial with BHV-7000 in idiopathic generalized epilepsy (IGE) with generalized tonic-clonic (GTC) seizures.
Authors
- Christopher Jensen
- Wesley T. Kerr (ORCID: https://orcid.org/0000-0002-5546-5951)
- Jacqueline A. French (ORCID: https://orcid.org/0000-0003-2242-8027)
- Lia Donahue
- Michelle DeGrosky
- Vladimir Coric
- Michael Bozik
- Vivian Suárez
- Nick Kozauer
- David Stock
- Irfan Qureshi
- Jason T. Lerner
Institutions
- University of Pittsburgh (US)
- Biohaven Pharmaceuticals (United States) (US)
- Comprehensive Clinical Research (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211240
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00